drugset / Trial / NCT06250062
A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicentre, randomized, double-blind, parallel, placebo-controlled Phase II clinical study of 261 adults with active ankylosing spondylitis to evaluate the efficacy and safety of JS005 in the treatment of active ankylosing spondylitis.
Timeline
- Start
- 2024-01-13
- Primary completion
- 2024-01-14
- Completion
- 2026-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROCONKIBART | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | ROCONKIBART | Monoclonal antibody | 300 mg | Subcutaneous |